Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial
Millot, F × Suciu, S Philippe, N Benoit, Y Mazingue, F Uyttebroeck, A Lutz, P Mechinaud, F Robert, A Boutard, P Marguerite, G Ferster, A Plouvier, E Rialland, X Behard, C Plantaz, D Dresse, M F Philippet, P Norton, L Thyss, A Dastugue, N Waterkeyn, Catherine Vilmer, E Otten, J Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer #
Grune & Stratton
Journal of Clinical Oncology vol:19 issue:7 pages:1935-42
The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.